Showing results (1831-1840 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|May 18, 2026
Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancerJordi Rodon, Bert O'Neil, Christopher Lim, et al.Investigational New Drugs|May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancerKhobe Chandran, Christina Guo, Simon Pacey, et al.Investigational New Drugs|September 14, 2026
First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumorsRachel Galot, Zahra Castel-Ajgal, Nuria Kotecki, et al.Investigational New Drugs|January 1, 1985
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study)J D Cowan, C K Osborne, J A Neidhart, et al.Investigational New Drugs|June 28, 2022
Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trialM Mego, D Svetlovska, De Angelis V, et al.Investigational New Drugs|August 29, 2020
Novel [l,2,4]triazolo[3,4-a]isoquinoline chalcones as new chemotherapeutic agents: Block IAP tyrosine kinase domain and induce both intrinsic and extrinsic pathways of apoptosisMagda F Mohamed, Farid M Sroor, Nada S Ibrahim, et al.Investigational New Drugs|May 28, 2021
Comparison of clinical features between immune-related sclerosing cholangitis and hepatitisMasaki Takinami, Akira Ono, Takanori Kawabata, et al.Investigational New Drugs|April 1, 1988
Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology GroupF Kung, F A Hayes, J Krischer, et al.Investigational New Drugs|April 1, 1988
Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanomaA Polyzos, S S Legha, A M Burgess, et al.Investigational New Drugs|January 1, 1986
Phase II study of 4'-deoxydoxorubicin in advanced colorectal cancerG Falkson, D A VorobiofPageof 372